<SEC-DOCUMENT>0001104659-21-088964.txt : 20210702
<SEC-HEADER>0001104659-21-088964.hdr.sgml : 20210702
<ACCEPTANCE-DATETIME>20210702170140
ACCESSION NUMBER:		0001104659-21-088964
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210702
DATE AS OF CHANGE:		20210702

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-230604
		FILM NUMBER:		211071150

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2121220d2_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supplement No. 1 dated July 2, 2021 to</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus Supplement dated October 1, 2020</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-230604</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To Prospectus dated April 12, 2019)</B></FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><IMG SRC="image_003.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Supplement No.&nbsp;1
to Prospectus Supplement supplements and amends the Prospectus Supplement dated October&nbsp;1, 2020 (the &ldquo;ATM Prospectus Supplement&rdquo;)
filed by us. This Supplement No.&nbsp;1 to the ATM Prospectus Supplement should be read in conjunction with the ATM Prospectus Supplement
and the base prospectus dated April&nbsp;12, 2019 (the &ldquo;Base Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have previously entered
into an ATM Equity Offering Sales Agreement, dated October 1, 2020 (the &ldquo;Sales Agreement&rdquo;) with BofA Securities, Inc. (&ldquo;BofA&rdquo;)
relating to our common stock (&ldquo;Shares&rdquo;), par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We filed the ATM Prospectus
Supplement to the Base Prospectus to register the offer and sale of our Shares from time to time through BofA, pursuant to the Sales Agreement,
having an aggregate offering price of up to $30,000,000 (the &ldquo;ATM Offering&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We terminated the Sales Agreement
on July 2, 2021. We sold a total of 3,296,123 Shares pursuant to the ATM Prospectus Supplement for total gross proceeds of approximately
$13.8&nbsp;million. The purpose of this Supplement No.&nbsp;1 to the ATM Prospectus Supplement is to terminate the ATM Offering under
the ATM Prospectus Supplement and the Base Prospectus, effective on the date of this Supplement No.&nbsp;1 to the ATM Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this Supplement No. 1 is July 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% .0# 2(  A$! Q$!_\0
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MMYT#HWMZ'W[5R/C/QV^C7<>C:-;_ &S6IL!4 W"+/3('5N^/Q-9WPRU!]/\
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MS[ UPWP:MGB\*W5PXPL]T2H]E4#^>?RK+\4^)+CQ[?IX7\,AI+5F#75U@A"
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M_P!D>_J:#*I4M[L=6Q_@6SOC?37L&Z#36)'EL=V\]@/IZU!XOEM=5UN&TTV
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MX?MO%=FGB?Q%&M_<7A+V\$O,5M%D[55>F<<DU=\)VC/J/B^.XA=8I]2<#<I
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M2:C>7=YX/,FDZ/-+NCAE!BWMM&YU0_=4G^5% 'KU%%% !1110 4444 %%%%
M!1110 4444 %%%% !7%ZA_R5[1O^P9/_ .A"BB@#M**** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
